Kalden J R, Manger B
Department of Internal Medicine III, University Erlangen-Nuremberg, Germany.
Curr Opin Rheumatol. 1996 May;8(3):195-200. doi: 10.1097/00002281-199605000-00005.
As in previous years, throughout 1995 biologic agents have been explored and tested in open and controlled clinical trials with regard to their efficacy in treating autoimmune rheumatic diseases, especially rheumatoid arthritis. Promising data have been collected from a placebo-controlled double-blind four-center study of a monoclonal anti-tumor necrosis factor-alpha antibody in rheumatoid arthritis patients. This type of treatment was demonstrated for the first time to effectively interfere with ongoing inflammatory processes in this disease entity. That anti-tumor necrosis factor-alpha treatment principles are of clinical value has also been shown in open trials applying tumor necrosis factor receptor constructs. Although undoubtedly the progress in the development of biologic agents for the treatment of inflammatory rheumatic diseases is steadily improving, new and unexpected side effects must be carefully controlled.
与往年一样，在1995年全年，人们对生物制剂进行了探索，并在开放和对照临床试验中测试了它们在治疗自身免疫性风湿性疾病，尤其是类风湿性关节炎方面的疗效。从一项针对类风湿性关节炎患者的单克隆抗肿瘤坏死因子-α抗体的安慰剂对照双盲四中心研究中收集到了有前景的数据。这种类型的治疗首次被证明能有效干扰该疾病实体中正在进行的炎症过程。在应用肿瘤坏死因子受体构建体的开放试验中也表明，抗肿瘤坏死因子-α治疗原则具有临床价值。尽管用于治疗炎症性风湿性疾病的生物制剂的开发进展无疑在稳步改善，但新的和意想不到的副作用必须得到仔细控制。
